Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939924 | 0.78 | ADK (0.46) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL868823 | 0.75 | ADK (0.49) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL26969443 | 0.75 | — | — | |
| SCHEMBL868204 | 0.72 | ADK (0.41) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL25612067 | 0.71 | ADK (0.46) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL30582615 | 0.71 | ADK (0.43) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL26107666 | 0.71 | ADK (0.43) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL2997320 | 0.68 | SLC22A12 (0.40) | SRCMEN1NR2F2KMT2A | |
| SCHEMBL20016712 | 0.68 | ADK (0.43) | ADKSRCMEN1NR2F2KMT2A | |
| SCHEMBL18658331 | 0.68 | ADK (0.40) | ADKSRCMEN1NR2F2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773836-B1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PROD INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | ADK 3728/4885SRC 2370/4885MEN1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.